Skip to content

PP&E (Net) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$7.66B+6.2%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$3.78M+7.0%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$10.57M-4.5%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$101.25M-7.6%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$3.63M-25.3%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$4.94M-26.2%

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's PP&E (net)?
Disc Medicine (IRON) reported PP&E (net) of $1.07M in Q1 2026.
How has Disc Medicine's PP&E (net) changed year-over-year?
Disc Medicine's PP&E (net) decreased by 21.9% year-over-year, from $1.37M to $1.07M.
What is the long-term trend for Disc Medicine's PP&E (net)?
Over 5 years (2020 to 2025), Disc Medicine's PP&E (net) has grown at a 31.6% compound annual growth rate (CAGR), from $294K to $1.16M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.